Santaris Pharma has appointed Mark Wedel as its vice president and chief medical officer. In these roles, he will be responsible for the company’s global therapeutic-development programs and therapeutic portfolio management.
The company said it has also named Stuart Mackey as its vice president of strategy and chief business officer. Mackey will lead Santaris’ corporate-strategy development, corporate communications, and global business-development programs, the company said.
Wedel was most recently senior vice president of drug development and chief medical officer at Isis Pharmaceuticals. Mackey previously held various roles at Amgen, most recently managing director of the firm’s venture capital affiliate, Amgen Ventures.
Both Wedel and Mackey will work out of Santaris’ recently created San Diego-based subsidiary (see RNAi News, 9/17/2009).